This week's roundup of Houston innovators includes Ben Jawdat of Revterra, Pete O'Heeron of FibroBiologics, and Jay Manouchehri of Fluence Analytics. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to clean energy — recently making headlines in Houston innovation.

Ben Jawdat, CEO and founder of Revterra

Ben Jawdat, CEO and founder of Revterra, joins the Houston Innovators Podcast. Photo via LinkedIn

Ben Jawdat founded Revterra in Houston based on a unique kinetic energy storage technology. The company has created away to better optimize existing grid-based electric vehicle charging ports while still minimizing a carbon footprint. The startup hopes to be a major player within the energy transition.

"We really want to be an enabling technology in the renewable energy transition," Jawdat says. "One part of that is facilitating the development of large-scale, high-power, fast-charging networks. But, beyond that, we see this technology as a potential solution in other areas related to the clean energy transition."

He shares more about what's next for Revterra on the podcast. Read more and listen to the episode.

Pete O'Heeron, CEO and chairman of FibroBiologics

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release. Read more.

Jay Manouchehri, CEO of Fluence Analytics

Fluence Analytics has exited to a multinational Japanese engineering and software giant. Image via FluenceAnalytics.com

Yokogawa, which has its US operations based in Sugar Land, acquired Fluence Analytics Inc. in a deal announced last week. The terms of the deal were not disclosed and, effective immediately, the company operate as Yokogawa Fluence Analytics. Jay Manouchehri, who joined the company in 2022, will continue to serve as CEO of the entity.

“Combining forces with Yokogawa Electric enables us to capture the full value of our unique data sets, and we can't wait to deliver this added value to our customers," Manouchehri says in a news release. "Together, we will enable autonomous operations and digital transformation in the polymer and biopharma industries."

Founded in 2012 in New Orleans, Fluence Analytics moved to Houston in 2021 following a $7.5 million venture capital raise led by Yokogawa Electric Corp., which has its North American headquarters in Sugar Land. Read more.

Fluence Analytics has exited to a multinational Japanese engineering and software giant. Image via FluenceAnalytics.com

Houston tech startup acquired by Tokyo-based multinational company

exit executed

A Houston company that provides analytics solutions within the chemicals industry has exited to a Japanese company.

Yokogawa acquired Fluence Analytics Inc. in a deal announced today. The terms of the deal were not disclosed and, effective immediately, the company operate as Yokogawa Fluence Analytics. Jay Manouchehri, who joined the company in 2022, will continue to serve as CEO of the entity.

“Combining forces with Yokogawa Electric enables us to capture the full value of our unique data sets, and we can't wait to deliver this added value to our customers," Manouchehri says in a news release. "Together, we will enable autonomous operations and digital transformation in the polymer and biopharma industries."

Founded in 2012 in New Orleans, Fluence Analytics moved to Houston in 2021 following a $7.5 million venture capital raise led by Yokogawa Electric Corp., which has its North American headquarters in Sugar Land.

The company's technology — automatic continuous online monitoring of polymerizations (ACOMP) product — provides real-time analytics solutions to polymer and biopharmaceutical companies worldwide. According to the company, its ACOMP product is the only commercially available system that can measure and analyze multiple polymer properties in real time, which leads to an improved system and less energy consumption and waste.

“Polymers are used in nearly every aspect of modern society in the form of plastics, rubber, paint, and so on," says Kenji Hasegawa, a Yokogawa Electric vice president and head of the Yokogawa Products Headquarters, in the release. "Combining Fluence Analytics' ACOMP system and other technology with our industry know-how will enable us to work with our customers to digitalize and automate polymerization processes that are currently monitored and adjusted manually.

"This will assist customers to improve worker safety, profitability, and environmental performance. We also plan to apply this technology to polymer re-use. We believe this is truly a game-changer for the industry,” he continues.

Fluence Analytics offices in Stafford, just southwest of Houston and has a team of 25 employees. Last fall, Fluence Analytics won in the Hardtech Category of the Houston Innovation Awards.

Here's why three New to Hou finalists from the Houston Innovation Awards have committed to Houston. Photo via Getty Images

Overheard: Why these 3 startups relocated to Houston

eavesdropping at the houston innovation awards gala

Houston is attracting more and more businesses big and small, old and new. So much that it seemed worthy of an award for the Houston Innovation Awards Gala.

The awards event, which is on November 9 and hosted by InnovationMap and Houston Exponential at the Ion, is honoring five finalists selected by judges — and naming one winner — who have recently relocated or significantly expanded to Houston.

Here's why three of these New to Hou finalists have committed to Houston.

"The move to the Houston area allowed us to be much closer to our strategic partners, customers and suppliers. We are also impressed by the vast talent pool in the area. Houston has a highly skilled workforce with diverse experiences, particularly in oil and gas, petrochemicals, and a broad range of technical areas."

Photo courtesy

Jay Manouchehri, CEO of Fluence Analytics, which relocated from Louisiana to Stafford last year, just outside of Houston. "We have been able to engage very actively with many customers since the move and also have developed valuable supplier relationships."

"In 2019, Chevron and EIC (both Houston based) became investors and we already had a lot of US clients, so we wanted to create a Houston footprint."

Photo courtesy

John van Pol, co-founder and CEO of INGU, which opened its new Houston office in 2021. Van Pol adds that the pandemic delayed their expansion initially.

"Houston has a quickly-growing biotechnology sector and already has existing oil and gas talent, making it an ideal place to find the people we need to grow our business."

Photo courtesy

Zimri T. Hinshaw, founder and CEO of BUCHA BIO, which relocated to Houston from New York in January 2022. "Our most prominent investor is Houston-based New Climate Ventures," he adds.

This week's roundup of Houston innovators includes Zain Shauk of Dream Harvest, Juliana Garaizar of Greentown Houston, and Jay Manouchehri of Fluence Analytics. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from sustainability to chemical analytics — recently making headlines in Houston innovation.

Zain Shauk, CEO of Dream Harvest

Zain Shauk, co-founder and CEO of Dream Harvest, joins the Houston Innovators Podcast just ahead of Earth Day. Photo courtesy of Dream Harvest

Zain Shauk is focused on future of farming, and the industry's success depends on making more environmentally friendly changes to the supply chain, and new technologies are enabling vertical indoor farming to effect these changes in some part. Shauk's company Dream Harvest recently received a $50 million investment from Orion Energy Partners to open a 100,000-square-foot indoor farming facility in Houston to scale production.

Shauk says he's also using the funding to support research and development to expand into other types of produce, but he has a lot to consider — affordability of the produce, maintaining sustainability, and more.

"It's going to take a lot of work and a lot of research. What I do know is we've come a long way with leafy greens," Shauk says. "When we started, we weren't growing in a way that makes financial sense with the amount of money we have to spend growing the product — and now we do." Click here to read more.

Juliana Garaizar, head of the Houston incubator and vice president of innovation

Greentown Houston's first year was surprising for Juliana Garaizar. Photo courtesy

Greentown Houston opened a year ago and, in just those 365 days, grew to over 60 member companies – something that took the original Boston-area location years. Juliana Garaizar says in a recent Q&A that this is due to companies outside of Houston looking for an entry point into the city for access to businesses, employees, and more. Specifically, she calls out Austin companies and businesses from Latin America.

"There are plenty of companies from Latin America coming over and choosing Houston as a landing pad and choosing Greentown as the place to start settling," she says. "We help them with funding. We help them with hiring local people." Click here to read more.

Jay Manouchehri, CEO of Fluence Analytics

Jay Manouchehri is now CEO of Fluence Analytics, and co-founder Alex Reed has transitioned to president and chief commercial officer. Photo courtesy of Fluence Analytics

Fluence Analytics, which moved its headquarters to the Houston area from New Orleans last year, has named Jay Manouchehri as the company's CEO. Manouchehri has worked in leadership roles within digital transformation at ABB and Honeywell all around the world, as well as in consulting and private equity.

Manouchehri tells InnovationMap he is focused on leading industrial growth.

“The next step for Fluence is really that we are industrializing our product and getting it into the industrial market," Manouchehri says. "That's exactly why we moved to Houston — it's where a lot of our clients are. We're building up and structure the company in such a manner that it could scale, get the right partnerships, and hire a team to take us to the next level and deliver the technology." Click here to read more.

Jay Manouchehri (left) is now CEO of Fluence Analytics, and co-founder Alex Reed has transitioned to president and chief commercial officer. Photo courtesy of Fluence Analytics

Exclusive: Houston startup names new CEO to lead industrial growth

next phase

Teamwork makes the dream work, and a Houston-based tech startup is one step closer to its dream team, according to the company's leadership.

Fluence Analytics, which moved its headquarters to the Houston area from New Orleans last year, has named Jay Manouchehri as the company's CEO. Manouchehri has worked in leadership roles within difital transformation at ABB and Honeywell all around the world, as well as in consulting and private equity.

"As you (can see) from Jay's background he is exactly the type of person we need to help take our company the next level," says co-founder Alex Reed. "I think he's gonna be critical as we did this Houston move and go to this next phase of growth and eventually drive to an exit."

Reed has transitioned from CEO to chief commercial officer, but Manouchehri tells InnovationMap the two really lead the company together and balance each other out. Reed says he's focused on commercial product strategy and Manouchehri is leading industrial growth.

“The next step for Fluence is really that we are industrializing our product and getting it into the industrial market," Manouchehri says. "That's exactly why we moved to Houston — it's where a lot of our clients are. We're building up and structure the company in such a manner that it could scale, get the right partnerships, and hire a team to take us to the next level and deliver the technology."

Fluence's technology is changing the game within the polymer space. The industrial and laboratory monitoring solutions — a combination of software and hardware — track and report key data in real time allowing industrial polymer producers to improve process control.

"When I saw what Alex is doing, it wasn't like it's a startup looking for a problem to solve. It's a startup trying to crack a nut that a lot of people in this industry have be in trying for 20 or 30 years and haven't been able to do so," Manouchehri says.

The move to Houston has allowed the company access to new and existing customers within the industry, but also potential acquirers and the company says an exit could be possible over the next few years. Additionally, Houston provides an opportunity to expand into the biomedical space. Recently, Fluence hired a Houston employee to build out this vertical.

"MRNAs and DNAs are all polymers. So, we use the same IP and same technology and do analysis, sensing, and data analytics for the biopharma industry," Manouchehri says. "We actually are pushing that quite strongly. Our client base is growing rapidly."

Another avenue Fluence is excited about is chemical recycling or polymerization recycling. Reed says they are closely watching the traction within the circular economy.

"Imagine taking plastic bottles and being able to recycle them back to the original molecule and then reprocess them into a bottle again," Reed says. "Mechanical recycling is more typical now and has a lot of disadvantages because of the additives and the properties that you get when you melt down all the different types of plastics. (Chemical recycling) would actually allow you to make new plastic from the old plastic, just by taking the original molecule out."

Fluence Analytics, which raised a $7.5 million round led by Energy Innovation Capital last summer, has its headquarters in Stafford, just southwest of Houston.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.